SCHEMBL5017703

SCHEMBL5017703

O=C(CC(F)(F)F)Nc1cc(-n2cncn2)nc(-c2cccs2)n1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 8/20 0.48
ADORA1 P30542 7/20 0.48
ADORA3 P0DMS8 4/20 0.48
SMN1; SMN2 Q16637 3/20 0.39
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39
HSD17B10 Q99714 2/20 0.39
LMNA P02545 1/20 0.39
PRNP P04156 1/20 0.38
NPC1 O15118 1/20 0.36
PKM P14618 1/20 0.36
HPGD P15428 1/20 0.36
RAB9A P51151 1/20 0.36
MAPT P10636 5/20 0.36
RXFP1 Q9HBX9 3/20 0.36
TP53 P04637 3/20 0.36
POLB P06746 1/20 0.36
THRB P10828 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28760680 0.88 ADORA2A (0.53) ADORA2AADORA1ADORA3SMN1; SMN2KDM4E
SCHEMBL5017904 0.87 ADORA2A (0.65) ADORA2AADORA1ADORA3KDM4EALDH1A1
SCHEMBL5017784 0.85 ADORA2A (0.49) ADORA2AADORA1ADORA3SMN1; SMN2KDM4E
SCHEMBL5024943 0.84 ADORA2A (0.63) ADORA2AADORA1ADORA3SMN1; SMN2KDM4E
SCHEMBL28760681 0.82 ADORA2A (0.47) ADORA2AADORA1ADORA3SMN1; SMN2KDM4E
SCHEMBL5016223 0.81 HDAC1 (0.43) ADORA2AADORA1ADORA3SMN1; SMN2ALDH1A1
SCHEMBL5016187 0.81 ADORA2A (0.54) ADORA2AADORA1ADORA3SMN1; SMN2ALDH1A1
SCHEMBL5026261 0.78 ADORA2A (0.50) ADORA2AADORA1ADORA3ALDH1A1
SCHEMBL27661589 0.73 ADORA2A (0.54) ADORA2AADORA1ADORA3PRNPMAPT
SCHEMBL5016113 0.73 ADORA2A (0.38) ADORA2AADORA1ADORA3KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-03-06 US claimed
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-03-06 US disclosed
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-03-06 US disclosed
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists ADORA2A, ADORA3, ADORA1 ADORA2A 1/4885ADORA1 3/4885ADORA3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.